Abstract #1386

FDA-Approved Intralipid Can Protect Hearts Against Ischemic Reperfusion Injury: An Integrated Cellular and Functional Cardiac MRI Study

Yijen Lin Wu¹, Brent D. Barbe¹, Li Liu¹, T. Kevin Hitchens¹, Chien Ho¹,²

¹Pittsburgh NMR Center for Biomedical Research, Carnegie Mellon University, Pittsburgh, PA, United States; ²Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, United States

Although timely restoration of coronary blood flow has greatly improved acute mortality after acute myocardial infarction (MI), the long-term prognosis and post-MI heart failure remain poor, because ischemic reperfusion injury (IRI) triggers inflammation, resulting in greater tissue damage and remodeling. We explored the potential protective effects of the FDA-approved Intralipid on the hearts after IRI. The in-situ inflammation of the heart is monitored with cellular MRI, whereas outcomes of the Intralipid treatment are evaluated with multi-parameter integrated cardiac MRI. Our results show that Intralipid can protect hearts against IRI.